Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: The STOP-HF randomized Phase II trial

European Heart Journal

Volumn 36, Issue 33, 2015, Pages 2228-2238

  Chung, Eugene S ^a   Miller, Leslie ^b   Patel, Amit N ^c   Anderson, Russell David ^d   Mendelsohn, Farrell O ^e   Traverse, Jay ^f   Silver, Kevin H ^g   Shin, Julia ^h   Ewald, Gregory ⁱ   Farr, Mary Jane ^j   Anwaruddin, Saif ^k   Plat, Francis ^l   Fisher, Scott J ^l   AuWerter, Alexander T ^l   Pastore, Joseph M ^l   Aras, Rahul ^l   Penn, Marc S ^g,l  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b BayCare Health Systems   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e Center for Therapeutic Angiogenesis   (United States)

^f MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^g Summa Cardiovascular Institute   (United States)

^h MONTEFIORE MEDICAL CENTER   (United States)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j Howard Hughes Medical Institute   (United States)

^k HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^l Juventas Therapeutics Inc ^*  (United States)

more..

Author keywords

Chronic heart failure; Endogenous tissue repair; Gene therapy; Stem cell homing

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PLACEBO; STROMAL CELL DERIVED FACTOR 1; TROPONIN I;

6 MIN WALK DISTANCE; ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CONTRAST ECHOCARDIOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DISEASE; HEART FAILURE; HEART FUNCTION TEST; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; ISCHAEMIC HEART FAILURE; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; NONVIRAL GENE THERAPY; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; ANALYSIS OF VARIANCE; CLINICAL TRIAL; GENE THERAPY; GENETICS; INTRALESIONAL DRUG ADMINISTRATION; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; CHEMOKINE CXCL12; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; GENETIC THERAPY; HEART FAILURE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MYOCARDIAL ISCHEMIA; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84941313402     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv254     Document Type: Article

References (33)

1. Askari A, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS. Effect of stromal-cellderived factor-1 on stem cell homing and tissue regeneration in ischemic cardiomyopathy. Lancet 2003;362:697-703.
2. Deglurkar I, Mal N, Mills WR, Popovic ZB, McCarthy P, Blackstone EH, Laurita KR, Penn MS. Mechanical and electrical effects of cell-based gene therapy for ischemic cardiomyopathy are independent. Hum Gene Ther 2006;17:1144-1151.
3. Unzek S, Zhang M, Mal N, Mills WR, Laurita KR, Penn MS. SDF-1 recruits cardiac stem cell like cells that depolarize in vivo. Cell Transplant 2007;16:879-886.
4. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, LosordoDW, Isner JM, Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003;107:1322-1328.
5. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON, Penn MS. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007;21:3197-3207.
6. Dong F, Harvey J, Finan A, Weber K, Agarwal U, Penn MS. Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Circulation 2012;126:314-324.
7. Sundararaman S, Miller TJ, Pastore JM, Kiedrowski M, Aras R, Penn MS. Plasmidbased transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure. Gene Therapy 2011;18:867-873.
8. Penn MS, Pastore J, Miller T, Aras R. SDF-1 in myocardial repair. Gene Therapy 2012; 19:583-587.
9. Cheng K, Malliaras K, Smith RR, Shen D, Sun B, Blusztajn A, Xie Y, Ibrahim A, Aminzadeh MA, Liu W, Li TS, De Robertis MA, Marban L, Czer LS, Trento A, Marban E. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Failure 2014; 2:49-61.
10. Penn MS, Mendelsohn FO, Schaer GL, Sherman W, Farr M, Pastore J, Rouy D, Clemens R, Aras R, Losordo DW. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res 2013;112:816-825.
11. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J, Evaluation MSGMIRC. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-1853.
12. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease I. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011;124:304-313.
13. Desbiens NA. A novel use for the word trend in the clinical trial literature. Am J Med Sci 2003;326:61-65.
14. Mathiasen AB, Qayyum AA, Jorgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, Haack-Sorensen M, Ekblond A, Kastrup J. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J 2015; doi:10.1093/eurheartj/ ehv196.
15. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003;108:457-463.
16. Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A. Agedependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2003;42:2073-2080.
17. Rota M, LeCapitaine N, Hosoda T, Boni A, De Angelis A, Padin-Iruegas ME, Esposito G, Vitale S, Urbanek K, Casarsa C, Giorgio M, Luscher TF, Pelicci PG, Anversa P, Leri A, Kajstura J. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res 2006;99: 42-52.
18. Schenk S, Mal N, Finan A, Zhang M, Kiedrowski M, Popovic Z, McCarthy PM, Penn MS. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007;25:245-251.
19. Vant HW, Mal N, Huang Y, Zhang M, Popovic Z, Forudi F, Deans R, Penn MS. Direct delivery of syngeneic and allogeneic large-scale expanded multipotent adult progenitor cells improves cardiac function after myocardial infarct. Cytotherapy 2007;9:477-487.
20. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11: 367-368.
21. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006;20:661-669.
22. Menasche P, Vanneaux V, Fabreguettes JR, Bel A, Tosca L, Garcia S, Bellamy V, Farouz Y, Pouly J, Damour O, Perier MC, Desnos M, Hagege A, Agbulut O, Bruneval P, Tachdjian G, Trouvin JH, Larghero J. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur Heart J 2015;36:743-750.
23. Penn MS. Importance of the SDF-1:CXCR4 axis in myocardial repair. Circ Res 2009; 104:1133-1135.
24. Schachinger V, Erbs S, Elsasser A, HaberboschW, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, HammCW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-1221.
25. Assmus B, Walter DH, Seeger FH, Leistner DM, Steiner J, Ziegler I, Lutz A, Khaled W, Klotsche J, Tonn T, Dimmeler S, Zeiher AM. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA 2013;309: 1622-1631.
26. Damas JK, Eiken HG, Oie E, Bjerkeli V, Yndestad A, Ueland T, Tonnessen T, Geiran OR, Aass H, Simonsen S, Christensen G, Froland SS, Attramadal H, Gullestad L, Aukrust P. Myocardial expression of CC-And CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 2000;47: 778-787.
27. LaRocca TJ, Schwarzkopf M, Altman P, Zhang S, Gupta A, Gomes I, Alvin Z, Champion HC, Haddad G, Hajjar RJ, Devi LA, Schecter AD, Tarzami ST. beta2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol 2010;56:548-559.
28. Pyo RT, Sui J, Dhume A, Palomeque J, Blaxall BC, Diaz G, Tunstead J, Logothetis DE, Hajjar RJ, Schecter AD. CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol 2006;41:834-844.
29. Bian J, Popovic ZB, Benejam C, Kiedrowski M, Rodriguez LL, Penn MS. Effect of cellbased intercellular delivery of transcription factor GATA4 on ischemic cardiomyopathy. Circ Res 2007;100:1626-1633.
30. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-Analytic approach. J Am Coll Cardiol 2010;56: 392-406.
31. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1-E7.
32. DiPersio JF. Diabetic stem-cell mobilopathy. N Engl J Med 2011;365: 2536-2538.
33. Golpanian S, El-Khorazaty J, Mendizabal A, DiFede DL, Suncion VY, Karantalis V, Fishman JE, Ghersin E, Balkan W, Hare JM. Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. J Am Coll Cardiol 2015;65: 125-132.